Varenicline (Champix, Chantix) has been available for use in smoking cessation since 2006. This drug has been associated with adverse cardiovascular events. Potential mechanisms for this association include modulation of parasymphathetic output from the brainstem to the heart, release of catecholamines and prothrombotic effect. We report the case of a 30-year-old man with no known cardiac disease, who developed thrombotic occlusion of left anterior descending artery and presented with acute coronary syndrome secondary to treatment with varenicline. The Naranjo probability scale indicates that varenicline was the probable cause of the myocardial infarction.
RigottiNAPipeALBenowitzNLArteagaCGarzaDTonstadS. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221-229.
2.
SinghSLokeYKSpanglerJGFurbergCD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011;183:1359-1366.
3.
Harrison-WoolrychMMaggoSTanMSavageRAshtonJ. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Saf. 2012;35:33-43.
4.
SvanströmHPasternakBHviidA. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012;345:e7176.
5.
SobierajDMWhiteWBBakerWL. Cardiovascular effects of pharmacologic therapies for smoking cessation. J Am Soc Hypertens. 2013;7:61-77.
6.
HaysJTEbbertJOSoodA. Efficacy and safety of varenicline for smoking cessation. Am J Med. 2008;121:32-42.
7.
Food and Drug Administration. FDA drug safety communication: safety review update of Chantix (varenicline) and risk of cardiovascular adverse events. http://www.fda.gov/Drugs/DrugSafety/ucm330367.htm. Accessed October 3, 2013.
8.
GonzalesDRennardSINidesM. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
9.
JorenbyDEHaysJTRigottiNA. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
10.
HaftJIKranzPDAlbertFJFaniK. Intravascular platelet aggregation in the heart induced by norepinephrine. Microscopic studies. Circulation. 1972;46:698-708.
11.
Sanz SanzCLMeyer García-SipidoEFuentes PonteMDel Nogal SáezF. Acute coronary syndrome: an uncommon serious complication of smoking cessation with varenicline [in Spanish; published online May 22, 2013]. Med Clin (Barc). doi:10.1016/j.medcli.2013.03.014.
